The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

Background G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with …

Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-
cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of …

Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …

Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …

The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab
and isatuximab, has significantly impacted the management of patients with multiple …

PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …

Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven
efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M …